The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer

SE Slater¹, P Patel^{1,2}, R Viney^{1,2}, M Foster³, E Porfiri², ND James^{1,2}, B Montgomery⁴, RT Bryan¹

¹University of Birmingham, UK

²University Hospitals Birmingham NHS Foundation Trust, UK

³Heart of England NHS Foundation Trust, UK

⁴Frimley Park Hospital NHS Foundation Trust, UK

ABSTRACT

INTRODUCTION Preliminary studies show that device assisted intravesical therapies appear more effective than passive diffusion intravesical therapy for the treatment of non-muscle invasive bladder cancer (NMIBC) in specific settings, and phase III studies are now being conducted. Consequently, we have undertaken a non-systematic review with the objective of describing the scientific basis and mechanisms of action of electromotive drug administration (EMDA) and chemohyperthermia (CHT).

METHODS PubMed, ClinicalTrials.gov and the Cochrane Library were searched to source evidence for this non-systematic review. Randomised controlled trials, systematic reviews and meta-analyses were evaluated. Publications regarding the scientific basis and mechanisms of action of EMDA and CHT were identified, as well as clinical studies to date.

RESULTS EMDA takes advantage of three phenomena: iontophoresis, electro-osmosis and electroporation. It has been found to reduce recurrence rates in NMIBC patients and has been proposed as an addition or alternative to bacillus Calmette–Guérin (BCG) therapy in the treatment of high risk NMIBC. CHT improves the efficacy of mitomycin C by three mechanisms: tumour cell cytotoxicity, altered tumour blood flow and localised immune responses. Fewer studies have been conducted with CHT than with EMDA but they have demonstrated utility for increasing disease-free survival, especially in patients who have previously failed BCG therapy.

CONCLUSIONS It is anticipated that EMDA and CHT will play important roles in the management of NMIBC in the future. Techniques of delivery should be standardised, and there is a need for more randomised controlled trials to evaluate the benefits of the treatments alongside quality of life and cost-effectiveness.

KEYWORDS

Bladder cancer – Urothelial cancer – Electromotive drug administration – Chemohyperthermia

Accepted 11 December 2013

CORRESPONDENCE TO

Richard Bryan, E: r.t.bryan@bham.ac.uk

In the Western world, bladder cancer is the fourth most common cancer in men and the ninth most common in women,¹ with a rising global incidence.^{2,3} In the UK, the disease accounts for approximately 10,000 new cases and 5,000 deaths per year.^{1,4} Over 90% of bladder cancers are transitional cell carcinomas of urothelial origin (urothelial carcinomas), and at presentation 75–85% will be non-muscle-invasive tumours (non-muscle-invasive bladder cancer [NMIBC], stages Ta/T1/Tis), with the remainder being muscle-invasive (stages T2–4).^{4–6}

Over half (50–55%) of bladder cancer patients present with Ta tumours, where recurrence is the main clinical issue, occurring in up to 80% of cases; for the 20–25% of patients presenting with T1 tumours, progression is the main clinical concern, occurring in up to 45% of cases.^{4,6} Progression to (or presentation with) muscle-invasive

disease (stages T2–4) represents a critical step, necessitating more radical and aggressive therapies, and carries a five-year survival rate of only 27–50%.^{4,6–8}

The four mechanisms of NMIBC recurrence are described as incomplete tumour resection, tumour cell reimplantation, the growth of microscopic tumours present (but undetected) at initial transurethral resection of a bladder tumour (TURBT) and ‘genuine’ new tumour formation.^{9,10} As highlighted by Brausi,¹¹ optimising all of our existing capabilities to abrogate each of these mechanisms could further improve our therapeutic impact on NMIBC, and new technologies should be seriously and critically evaluated, not only for efficacy but also for cost-effectiveness.¹²

In this regard, device-assisted intravesical chemotherapy regimens appear to show improved efficacy versus passive diffusion regimens: studies comparing electromotive drug

administration (EMDA) and chemohyperthermia (CHT) with conventional treatment have yielded promising results, demonstrating potential to improve intravesical therapy for NMIBC patients.¹⁵ In this review, we outline the scientific basis and mechanisms of action of EMDA and CHT, present a brief summary of their clinical utility and highlight important areas for future studies.

Methods

PubMed, ClinicalTrials.gov and the Cochrane Library were searched to source evidence for this non-systematic review. Search terms used included 'EMDA', 'hyperthermia' and 'bladder cancer'. Randomised controlled trials (RCTs), systematic reviews and meta-analyses were evaluated primarily. Thirty-four papers were selected for this review.

Results

Electromotive drug administration

EMDA uses an electric current to enhance transepithelial drug penetration.¹⁴ EMDA is administered via a battery powered generator delivering an electric current of 0–30mA DC at 0–55V, which is passed between two electrodes:¹⁵ an active electrode is placed into the bladder as part of a transurethral catheter, and dispersive ground electrode pads are placed on the skin of the lower abdomen.

EMDA takes advantage of three phenomena: iontophoresis, electro-osmosis and electroporation. Iontophoresis involves propelling a substance into tissues by passing an electrical current through a solution containing the active charged ingredient.¹⁶ Electro-osmosis transports non-ionised polar molecules (eg mitomycin C [MMC]) against their columbic gradients when there is convective flow of water in association with ions.¹⁶ Electroporation is the increase in electrical conductivity and permeability of cell plasma membranes due to the application of an electrical field.¹⁶

MMC is a polar and non-ionised molecule in the range of pHs that may be present in the bladder (4.5–8.5).¹⁷ It is delivered in a solution of Na⁺/Cl⁻/MMC, and when a current with a positive polarity is applied to this solution, the sodium ions move via iontophoresis and MMC molecules are carried with them via electro-osmosis, increasing the rate and depth of delivery.¹⁷

In vitro studies demonstrate that the penetration of MMC into non-cancerous bladder wall with EMDA is significantly greater than that achieved by passive diffusion (PD) alone:^{16,17} concentration measurements made in the urothelium, lamina propria and muscularis layers are significantly greater for EMDA at all levels than for PD (EMDA increases MMC delivery by 4–7 times).¹⁷ In these studies, penetration of the drug into the muscularis propria was insufficient to inhibit a significant proportion of the proliferating cells in this layer,¹⁸ but as cancerous tissue is more permeable to water and solute than normal urothelium, the drug concentration in bladder tumours may be sufficient to achieve inhibition of proliferating cells in the muscularis propria.¹⁹

In terms of efficacy, the results of published EMDA clinical trials are summarised in Table 1. The majority of these studies have evaluated EMDA MMC as first-line intravesical therapy following TURBT (adjuvant therapy) and there remains a paucity of evidence supporting the use of EMDA MMC following failure of bacillus Calmette–Guérin (BCG) therapy.²⁰ In terms of tolerability, the use of EMDA MMC in clinical practice to date has never resulted in haematological toxicity, severe allergic reactions, life-threatening adverse events or any treatment-related deaths.²¹

Chemohyperthermia

The effect of hyperthermia on cancer cells has been investigated since the 1950s and the use of CHT to manage bladder cancer has recently been the subject of a systematic review.²² The review indicated potential for CHT in becoming a part of standard therapy for high-risk NMIBC patients with recurrent tumours who are unsuitable for radical cystectomy or who have contraindications for BCG therapy. The Synergo® SB-TS 101 (Medical Enterprises, Amsterdam, Netherlands) system is currently the most common system of CHT delivery,²³ using a radiofrequency generator to deliver radiofrequency (heat) energy at 915MHz.

The Combat BRS (Combat Medical, Wheathampstead, UK) system is now also in the marketplace, using a heat exchanger instead of a radiofrequency system. There is a theoretical independent advantage of radiofrequency energy for tumour cell killing, additional to hyperthermia, but a heat exchange fluid recirculation system is likely to reduce hot and cold spots and burning of the bladder wall.²⁴ However, until the Combat BRS system becomes more widely used, direct comparisons cannot be made.

Hyperthermia affects the tumour cell directly, the vascular supply to the tumour and it also triggers an immune response.²⁵

- > Hyperthermia induces cell killing (cytotoxicity) above 40.5°C: up to 43°C there is linear growth arrest involving reduced ribonucleic acid/deoxyribonucleic acid (DNA) synthesis and cell cycle arrest; exponential growth arrest occurs above 43°C along with impaired DNA repair.²⁵
- > Increasing temperatures can alter blood flow, and so the vascular effects of hyperthermia are dependent on the type and size of tumour. Increasing the temperature to 43°C increases tumour blood flow by vasodilation, allowing more MMC to be delivered, while above 43°C, tumour blood flow is reduced, possibly limiting the oxygen supply to the tumour (swelling/lysis of endothelial cells, adherence of leucocytes to vessels, increased rigidity of red blood cells, increased blood viscosity).²⁶ Tumour vasculature is less able to dissipate heat and cancer cells are therefore more likely to be heat damaged than non-cancerous cells.²⁶
- > On heating, the tumour microenvironment becomes increasingly hypoxic and acidic, further increasing the sensitivity of cells to both heat and cytotoxic therapeutics,²⁶ and angiogenesis is inhibited by the upregulation of plasminogen activator inhibitor-1 in endothelial cells.²⁷

Table 1 Summary of comparative electromotive drug administration study results to date

Study	Number of patients	Arm 1	Arm 2	Arm 3	Arm 1 outcome	Arm 2 outcome	Arm 3 outcome	p-value
Di Stasi, 2006 ¹⁵	212 (T1)	Post-TURBT BCG (induction, then maintenance for responders)	Post-TURBT BCG followed by EMDA MMC (induction, then maintenance for responders)		DF interval 21 mths 57.9% RR (88 mths) 21.9% PR (88 mths) DS mortality 16.2% (88 mths)	DF interval 69 mths 41.9% RR (88 mths) 9.3% PR (88 mths) DS mortality 5.6% (88 mths)		0.0012 0.0012 0.004 0.01
Di Stasi, 2011 ²¹	374	TURBT alone	Post-TURBT PD MMC	Pre-TURBT EMDA MMC	DF interval 12 mths 64% RR (86 mths)	DF interval 16 mths 59% RR (86 mths)	DF interval 52 mths 38% RR (86 mths)	<0.0001 <0.0001
Brausi, 1998 ³⁴	28 (G1/G2, Ta/T1)	Pre-TURBT PD MMC	Pre-TURBT EMDA MMC		41.6% CR 60% RR in responders (7.6 mths) DF interval 10.5 mths	40% CR 33% RR in responders (6 mths) DF interval 14.5 mths		
Di Stasi, 2003 ³⁵	108 (multifocal Tis, incl 98 T1)	Post-TURBT PD MMC ('maintenance')	Post-TURBT EMDA MMC ('maintenance')	Post-TURBT BCG ('maintenance')	28% CR (3 mths) 31% CR (6 mths) Median time to recurrence 19.5 mths	53% CR (3 mths) 58% CR (6 mths) Median time to recurrence 35 mths	56% CR (3 mths) 64% CR (6 mths) Median time to recurrence 26 mths	

TURBT = transurethral resection of bladder tumour; BCG = bacillus Calmette–Guérin; EMDA = electromotive drug administration; MMC = mitomycin C; DF = disease free; RR = recurrence rate; PR = progression rate; DS = disease specific; CR = complete response; PD = passive diffusion

- > Hyperthermia mimics the increased body temperature seen in fever,²⁸ stimulating an immune response constituting multiple changes to enhance immune surveillance:²⁹ induction of heat shock proteins can prime CD8+ cytotoxic T-cells and lead to autovaccination against the tumour²⁵ as well as increased natural killer cell infiltration, increased migration and adhesion of lymphocytes, increased T-cell and antibody numbers, increased concentrations of cytokines and acute phase proteins, and a lowering of the activation threshold required for many immune system effector molecules.^{25,28}

In vitro studies have shown that hyperthermia also has a synergistic effect on MMC administration.³⁰ This is potentially caused by increased MMC uptake by heated tumour cells, increased drug activation and tumour cells being less able to counteract MMC's cytotoxic effects.²⁵

The 2011 systematic review by Lammers *et al* of 22 studies indicated a 59% reduction in NMIBC recurrence rate when CHT is compared with MMC alone, and an improved bladder preservation rate (87.6%) could be a significant benefit of this treatment regimen.²² However, definitive

conclusions could not be drawn owing to the limited number of RCTs and heterogeneity in the study designs.

Subsequently, Moskovitz *et al* published their ten-year experience with CHT in both the adjuvant (CHT delivered after primary therapy, TURBT) and neoadjuvant settings (CHT delivered before primary therapy), demonstrating 72% recurrence-free survival for the adjuvant protocol with a progression rate of 4.7%.³¹ They achieved an initial complete response of 79% for their neoadjuvant protocol, with 84% of these patients remaining free from recurrence. The use of CHT MMC in the setting of patients experiencing recurrence following induction or maintenance BCG is being assessed in the UK's HYMN RCT (CHT MMC vs a second course of BCG or standard therapy), which, at the time of writing, is in the patient follow-up phase.

The currently available CHT trial data on side effects and adverse events are limited.²² However, preliminary results reveal that bladder spasms and pain are the most common side effects, reported in around 20% of patients during active treatment, along with mild and transient lower urinary tract symptoms following the procedure.²²

Two studies report a contracted bladder and severe urinary incontinence but the cause of these adverse events was not certain. Side effects are slightly more frequent than in PD MMC patients but, as suggested by Lammers *et al*, a structured questionnaire for adverse events is recommended in future research for effective evaluation.²²

Discussion

The effective treatment of NMIBC encompasses a range of different procedures and interventions, and improvements to all of these areas should be considered as we strive to enhance both outcomes and quality of life for NMIBC patients.¹² Optimising our existing intravesical chemotherapy regimens is just one aspect albeit an important one. In this review, we see that both EMDA and CHT appear safe and effective in reducing recurrence of NMIBC although more data are needed. Whereas the mechanism of EMDA is quite simple (increasing the rate and depth of MMC delivery to the urothelium), the effects of hyperthermia are varied and have not yet been elucidated thoroughly.

EMDA has been studied more extensively in RCTs than CHT, and there is evidence to support its utility for the treatment of high-risk NMIBC as an alternative to or in addition to BCG and, possibly, perioperatively. Larger, adequately powered RCTs should be carried out to further evaluate the addition of EMDA to current BCG therapy. Studies are also needed to evaluate whether the timing of EMDA administration alters efficacy, either prior to TURBT (perioperative or neoadjuvant) or following TURBT (adjuvant). Radical cystectomy should be the default position following failure of intravesical BCG²⁰ although bladder-sparing options may be desirable for the very elderly or patients unfit for cystectomy. While beyond the scope of this review, to date, bladder-sparing options following BCG failure only achieve recurrence-free survival of around 50% at up to two years²⁰ and evaluation of EMDA is required in this setting.

With regard to CHT, there are only a small number of completed RCTs and so more evidence is required before definitive conclusions can be drawn and before practice could change.²² We eagerly await the results of the HYMN trial. In addition, CHT protocols must be standardised, including variables such as duration and temperature as well as the equipment/delivery system used.

There remain a number of questions to be answered for both EMDA and CHT, and a coordinated series of carefully conducted clinical trials are needed to address these. Both modalities are, however, interesting and seemingly effective, and they are likely to form an important part of our NMIBC armamentarium in the future. Trials to directly compare the clinical effectiveness and cost-effectiveness of EMDA and CHT, as well as effects on quality of life, may also be necessary before implementation into routine clinical practice. Nevertheless, it is important to note that there have been no new therapeutic agents developed for bladder cancer in over a decade and we should continue our search for such agents in parallel to developing new strategies for the administration of existing agents.^{32,33}

Conclusions

The potential advantages of EMDA and CHT are important in the management of NMIBC. However, the techniques and timing of delivery must be standardised, and there is a need for more RCTs to evaluate not only the benefits of the treatments in terms of disease-specific outcomes but also quality of life and cost-effectiveness. It is anticipated that these therapies will play a significant role in the management of NMIBC in the future but we should not forget the urgent and ongoing unmet need for new therapeutic agents to treat patients with bladder cancer.

References

1. Burger M, Catto JW, Dalbagni G *et al*. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol* 2013; **63**: 234–241.
2. Ploeg M, Aben KK, Kiemeny LA. The present and future burden of urinary bladder cancer in the world. *World J Urol* 2009; **27**: 289–293.
3. van Rhijn BW, Burger M, Lotan Y *et al*. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. *Eur Urol* 2009; **56**: 430–442.
4. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. *Lancet* 2009; **374**: 239–249.
5. Lorusso V, Silvestris N. Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions. *Ann Oncol* 2005; **16**: iv85–iv89.
6. Wallace DM, Bryan RT, Dunn JA *et al*. Delay and survival in bladder cancer. *BJU Int* 2002; **89**: 868–878.
7. James ND, Hussain SA, Hall E *et al*. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *N Engl J Med* 2012; **366**: 1,477–1,488.
8. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. *Eur Urol* 2005; **48**: 202–205.
9. Bryan RT, Collins SI, Daykin MC *et al*. Mechanisms of recurrence of Ta/T1 bladder cancer. *Ann R Coll Surg Engl* 2010; **92**: 519–524.
10. Kondás J, Kiss L, Határ A *et al*. The effect of intravesical mitomycin C on the recurrence of superficial (Ta–T1) bladder cancer. A Hungarian multicenter study. *Int Urol Nephrol* 1999; **31**: 451–456.
11. Brausi M. Are new technologies for detection and treatment of non-muscle-invasive bladder cancer (NMIBC) so important? A plea for adoption by teaching programs to improve results after standard white light transurethral resection of NMIBC. *Eur Urol* 2012; **61**: 914–916.
12. Bryan RT. Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C. *Eur Urol* 2012; **62**: 803–805.
13. Logan C, Brown M, Hayne D. Intravesical therapies for bladder cancer – indications and limitations. *BJU Int* 2012; **110** Suppl 4: 12–21.
14. Giannantoni A, Di Stasi SM, Chancellor MB *et al*. New frontiers in intravesical therapies and drug delivery. *Eur Urol* 2006; **50**: 1,183–1,193.
15. Di Stasi SM, Giannantoni A, Giurioli A *et al*. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol* 2006; **7**: 43–51.
16. Di Stasi SM, Vespasiani G, Giannantoni A *et al*. Electromotive delivery of mitomycin C into human bladder wall. *Cancer Res* 1997; **57**: 875–880.
17. Di Stasi SM, Giannantoni A, Massoud R *et al*. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. *Cancer Res* 1999; **59**: 4,912–4,918.
18. Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. *Cancer Res* 1991; **51**: 3,849–3,856.
19. Hicks RM, Ketterer B, Warren RC. The ultrastructure and chemistry of the luminal plasma membrane of the mammalian urinary bladder: a structure with low permeability to water and ions. *Philos Trans R Soc Lond B Biol Sci* 1974; **268**: 23–38.
20. Yates DR, Brausi MA, Catto JW *et al*. Treatment options available for bacillus Calmette–Guérin failure in non-muscle-invasive bladder cancer. *Eur Urol* 2012; **62**: 1,088–1,096.

21. Di Stasi SM, Valenti M, Verri C *et al.* Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. *Lancet Oncol* 2011; **12**: 871–879.
22. Lammers RJ, Witjes JA, Inman BA *et al.* The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2011; **60**: 81–93.
23. van der Heijden AG, Kiemeny LA, Gofrit ON *et al.* Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. *Eur Urol* 2004; **46**: 65–71.
24. Webb H, Lubner MG, Hinshaw JL. Thermal ablation. *Semin Roentgenol* 2011; **46**: 133–141.
25. Rampersaud EN, Vujaskovic Z, Inman BA. Hyperthermia as a treatment for bladder cancer. *Oncology* 2010; **24**: 1,149–1,155.
26. Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. *Cancer Res* 1984; **44**: 4721s–4730s.
27. Roca C, Primo L, Valdembri D *et al.* Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. *Cancer Res* 2003; **63**: 1,500–1,507.
28. Peer AJ, Grimm MJ, Zynda ER, Repasky EA. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. *Immunol Res* 2010; **46**: 137–154.
29. Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. A brief overview. *In Vivo* 2006; **20**: 689–695.
30. van der Heijden AG, Jansen CF, Verhaegh G *et al.* The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. *Eur Urol* 2004; **46**: 670–674.
31. Moskovitz B, Halachmi S, Moskovitz M *et al.* 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. *Future Oncol* 2012; **8**: 1,041–1,049.
32. Bryan RT and James ND. Bladder Cancer: Time for a Rethink? *Oncology* (Williston Park) 2011; **25**: 965–8.
33. Bryan RT, Kirby R, O'Brien T, Mostafid H. So much cost, such little progress. *Eur Urol* 2014 (in print).
34. Brausi M, Campo B, Pizzocaro G *et al.* Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. *Urology* 1998; **51**: 506–509.
35. Di Stasi SM, Giannantoni A, Stephen RL *et al.* Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. *J Urol* 2003; **170**: 777–782.